Abstract
Although peptides notoriously have poor intrinsic pharmacokinetic properties, it is well-known that nanostructures with excellent pharmacokinetic properties can be designed. Noticing that peptide inhibitors are generally nonpolar, here, we consolidate the peptide inhibitor targeting intracellular protein–protein interactions (PPIs) as an integral part of biodegradable self-assembled depsipeptide nanostructures (SdPNs). Because the peptide inhibitor has the dual role of PPI inhibition and self-assembly in this design, problems associated with the poor pharmacokinetics of peptides and encapsulation/entrapment processes can be overcome. Optimized SdPNs displayed better tumor targeting and PPI inhibition properties than the comparable small molecule inhibitor in vivo. Kinetics of PPI inhibition for SdPNs were gradual and controllable in contrast to the rapid inhibition kinetics of the small molecule. Because SdPN is modular, any appropriate peptide inhibitor can be incorporated into the platform without concern for the poor pharmacokinetic properties of the peptide.
Original language | English |
---|---|
Pages (from-to) | 104-113 |
Number of pages | 10 |
Journal | Journal of Controlled Release |
Volume | 366 |
DOIs | |
State | Published - Feb 2024 |
Bibliographical note
Publisher Copyright:© 2023 Elsevier B.V.
Keywords
- Biodegradable
- Depsipeptide
- Peptide inhibitor
- Protein-protein interactions
- Self-assembly